David E. Leahy - Concepedia

Author

David E. Leahy

Also Known As

D E Leahy, D LEAHY, D Leahy, D. E. LEAHY, D. E. Leahy, D.E Leahy, D.E. Leahy, David E Leahy, David E. Leahy, David Leahy

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)University of Manchester C4X Discovery (United Kingdom)Joint Research Centre Cyprotex (United States)

About

David E. Leahy is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.5K
2	Engineering	10	13	456
3	Natural Sciences	3	3	176
4	Business	1	1	53
5	Health Sciences	1	1	73

David E. Leahy

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Cross-validation pitfalls when selecting and assessing regression and classification models Damjan Krstajić, Ljubomir Buturović, David E. Leahy, Journal of Cheminformatics	2014	1K
Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases Trudy Rodgers, David E. Leahy, Malcolm Rowland Journal of Pharmaceutical Sciences Pharmacokinetic ModelingMedicinePhysiologyTissue DistributionPharmacotherapy	2005	765
GPTIPS: An Open Source Genetic Programming Toolbox For Multigene Symbolic Regression Dominic P. Searson, David E. Leahy, Mark J. Willis	2010	333
Metabolism: A Bottleneck in <i>In Vitro</i> Toxicological Test Development Sandra Coecke, H J Ahr, Bas J. Blaauboer, Alternatives to Laboratory Animals MedicinePhysiologyToxicology TestingToxicologyExperimental Toxicology	2006	175
Intrinsic Molecular Volume as a Measure of the Cavity Term in Linear Solvation Energy Relationships: Octanol-Water Partition Coefficients and Aqueous Solubilities David E. Leahy Journal of Pharmaceutical Sciences EngineeringCavity TermPhysicochemical AnalysisNatural SciencesPhysical Chemistry	1986	148
Tissue Distribution of Basic Drugs: Accounting for Enantiomeric, Compound and Regional Differences Amongst β-Blocking Drugs in Rat Trudy Rodgers, David E. Leahy, Malcolm Rowland Journal of Pharmaceutical Sciences Molecular PharmacologyPharmacological StudyMedicinePhysiologyTissue Distribution	2005	130
Model solvent systems for QSAR. Part 3. An LSER analysis of the ‘critical quartet.’ New light on hydrogen bond strength and directionality David E. Leahy, Jeffrey J. Morris, Peter J. Taylor, Journal of the Chemical Society Perkin Transactions 2	1992	91
Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda Michel Bouvier d’Yvoire, Pilar Prieto, Bas J. Blaauboer, Alternatives to Laboratory Animals PhysiologyEcvam Workshop 63Physiologically-based Kinetic ModellingApplied PhysiologyKinetics (Physics)	2007	73
Model Solvent Systems for QSAR Part I. Propylene Glycol Dipelargonate (PGDP). A new Standard Solvent for use in Partition Coefficient Determination David E. Leahy, Peter J. Taylor, Alan R. Wait Quantitative Structure-Activity Relationships Proteinlipid InteractionEngineeringChemical AnalysisOrganic ChemistryChemistry	1989	67
Model solvent systems for QSAR. Part 2. Fragment values (‘f-values’) for the ‘critical quartet’ David E. Leahy, Jeffrey J. Morris, Peter J. Taylor, Journal of the Chemical Society Perkin Transactions 2	1992	67

Page 1